FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038349091> ?p ?o ?g. }

• W2038349091 endingPage "2714" @default.
• W2038349091 startingPage "2706" @default.
• W2038349091 abstract "Purpose This study assessed the efficacy and safety of linifanib in patients with advanced renal cell carcinoma (RCC) who were previously treated with sunitinib. Materials and methods This open-label, multicentre, phase 2 trial of oral linifanib 0.25 mg/kg/day enrolled patients who had prior nephrectomy and adequate organ function. The primary end-point was objective response rate (ORR) per response evaluation criteria in solid tumors (RECIST) by central imaging. Secondary end-points were progression-free survival (PFS), overall survival (OS) and time to progression (TTP). Safety was also assessed. Results Fifty-three patients, median age 61 years (range 40–80) were enrolled (August 2007 to October 2008) across 12 North-American centres. Median number of prior therapies was 2 (range 1–4); 43 patients (81%) had clear-cell histology. ORR was 13.2%, median PFS was 5.4 months (95% Confidence Interval (CI): 3.6, 6.0) and TTP was the same; median OS was 14.5 months (95% CI: 10.8, 24.1). The most common treatment-related adverse events (AEs) were diarrhoea (74%), fatigue (74%) and hypertension (66%), and the most common treatment-related Grade 3/4 AE was hypertension (40%). Conclusions Linifanib demonstrated clinically meaningful activity in patients with advanced RCC after sunitinib failure. At 0.25 mg/kg/day, significant dose modifications were required. An alternative, fixed-dosing strategy is being evaluated in other trials." @default.
• W2038349091 created "2016-06-24" @default.
• W2038349091 creator A5009262570 @default.
• W2038349091 creator A5015225025 @default.
• W2038349091 creator A5019778989 @default.
• W2038349091 creator A5025919899 @default.
• W2038349091 creator A5027683140 @default.
• W2038349091 creator A5028789952 @default.
• W2038349091 creator A5036138286 @default.
• W2038349091 creator A5037536965 @default.
• W2038349091 creator A5038365482 @default.
• W2038349091 creator A5041491201 @default.
• W2038349091 creator A5052504518 @default.
• W2038349091 creator A5058115259 @default.
• W2038349091 creator A5069070518 @default.
• W2038349091 creator A5077401758 @default.
• W2038349091 creator A5080231807 @default.
• W2038349091 creator A5087150696 @default.
• W2038349091 creator A5087150838 @default.
• W2038349091 creator A5089516753 @default.
• W2038349091 date "2011-12-01" @default.
• W2038349091 modified "2023-10-18" @default.
• W2038349091 title "Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure" @default.
• W2038349091 cites W1503899947 @default.
• W2038349091 cites W2034548257 @default.
• W2038349091 cites W2061790725 @default.
• W2038349091 cites W2070580351 @default.
• W2038349091 cites W2076017354 @default.
• W2038349091 cites W2078419070 @default.
• W2038349091 cites W2086506462 @default.
• W2038349091 cites W2098364798 @default.
• W2038349091 cites W2100669312 @default.
• W2038349091 cites W2102056525 @default.
• W2038349091 cites W2106453307 @default.
• W2038349091 cites W2112940666 @default.
• W2038349091 cites W2118677643 @default.
• W2038349091 cites W2130842796 @default.
• W2038349091 cites W2139248078 @default.
• W2038349091 cites W2142297664 @default.
• W2038349091 cites W2143737148 @default.
• W2038349091 cites W2149456801 @default.
• W2038349091 cites W2152190103 @default.
• W2038349091 cites W2152456993 @default.
• W2038349091 cites W2153867442 @default.
• W2038349091 cites W2163423568 @default.
• W2038349091 cites W2166788033 @default.
• W2038349091 cites W4253705647 @default.
• W2038349091 doi "https://doi.org/10.1016/j.ejca.2011.09.002" @default.
• W2038349091 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4167844" @default.
• W2038349091 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22078932" @default.
• W2038349091 hasPublicationYear "2011" @default.
• W2038349091 type Work @default.
• W2038349091 sameAs 2038349091 @default.
• W2038349091 citedByCount "29" @default.
• W2038349091 countsByYear W20383490912012 @default.
• W2038349091 countsByYear W20383490912013 @default.
• W2038349091 countsByYear W20383490912014 @default.
• W2038349091 countsByYear W20383490912015 @default.
• W2038349091 countsByYear W20383490912016 @default.
• W2038349091 countsByYear W20383490912017 @default.
• W2038349091 countsByYear W20383490912018 @default.
• W2038349091 countsByYear W20383490912023 @default.
• W2038349091 crossrefType "journal-article" @default.
• W2038349091 hasAuthorship W2038349091A5009262570 @default.
• W2038349091 hasAuthorship W2038349091A5015225025 @default.
• W2038349091 hasAuthorship W2038349091A5019778989 @default.
• W2038349091 hasAuthorship W2038349091A5025919899 @default.
• W2038349091 hasAuthorship W2038349091A5027683140 @default.
• W2038349091 hasAuthorship W2038349091A5028789952 @default.
• W2038349091 hasAuthorship W2038349091A5036138286 @default.
• W2038349091 hasAuthorship W2038349091A5037536965 @default.
• W2038349091 hasAuthorship W2038349091A5038365482 @default.
• W2038349091 hasAuthorship W2038349091A5041491201 @default.
• W2038349091 hasAuthorship W2038349091A5052504518 @default.
• W2038349091 hasAuthorship W2038349091A5058115259 @default.
• W2038349091 hasAuthorship W2038349091A5069070518 @default.
• W2038349091 hasAuthorship W2038349091A5077401758 @default.
• W2038349091 hasAuthorship W2038349091A5080231807 @default.
• W2038349091 hasAuthorship W2038349091A5087150696 @default.
• W2038349091 hasAuthorship W2038349091A5087150838 @default.
• W2038349091 hasAuthorship W2038349091A5089516753 @default.
• W2038349091 hasBestOaLocation W20383490912 @default.
• W2038349091 hasConcept C126322002 @default.
• W2038349091 hasConcept C126894567 @default.
• W2038349091 hasConcept C141071460 @default.
• W2038349091 hasConcept C143998085 @default.
• W2038349091 hasConcept C159641895 @default.
• W2038349091 hasConcept C197934379 @default.
• W2038349091 hasConcept C203092338 @default.
• W2038349091 hasConcept C2777288759 @default.
• W2038349091 hasConcept C2777472916 @default.
• W2038349091 hasConcept C2779490328 @default.
• W2038349091 hasConcept C31760486 @default.
• W2038349091 hasConcept C535046627 @default.
• W2038349091 hasConcept C71924100 @default.
• W2038349091 hasConcept C90924648 @default.
• W2038349091 hasConceptScore W2038349091C126322002 @default.
• W2038349091 hasConceptScore W2038349091C126894567 @default.

• next